Journal
EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 16, Issue 1, Pages 31-44Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737175.2016.1123094
Keywords
Fingolimod; mechanism of action; multiple sclerosis; safety; efficacy; non-therapeutic effects
Categories
Funding
- Acorda Therapeutics
- Alkermes
- Bayer
- Biogen Idec
- Genzyme
- GlaxoSmithKline
- Novartis Pharmaceuticals Corporation
- Pfizer
- Questcor
- Serono
- Teva Pharmaceuticals
- XenoPort QuestCor
- Acorda
- Biogen
- Chugai
- Eli Lilly
- EMD Serono
- Novartis
- Ono
- Opexa
- Roche
- Sanofi
- Teva
- Genenetech
- Novartis Pharmaceuticals Corporation, USA
Ask authors/readers for more resources
Fingolimod is an orally administered, first-in-class therapy for the treatment of relapsing forms of multiple sclerosis. Data from pivotal clinical trials show that fingolimod has a robust, significant effect on annualized relapse rates and MRI outcomes. Fingolimod has a novel, well-characterized mechanism of action. It acts through a specific set of receptors, sphingosine 1-phosphate receptors, present on the surface of a wide range of human cells and tissues, including neural cells, neurons and lymphocytes. Here we review the current literature to describe the mechanism of action of fingolimod in the context of its well-established clinical efficacy and safety profile. Understanding of the mechanisms behind any non-therapeutic effects of fingolimod facilitates their prediction and management in the clinical setting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available